Skip to main content
. 2013 Nov 30;35(4):784–794. doi: 10.1093/carcin/bgt390

Fig. 3.

Fig. 3.

WNT5A promotes aerobic glycolysis in melanoma cells. (A) Extracellular lactate concentration in A2058 cells treated with rWNT5A or carrier overnight. N = 4. (B) Extracellular lactate concentration in A2058 cells treated with carrier, rWNT5A or rWNT5A + Box5 peptide for 12h. N = 8. (C) Extracellular lactate concentration in A2058 cells following 48h of transfection with two WNT5A targeting siRNAs (S1 and S2) compared to a control scrambled siRNA (N). N = 4. (D) Extracellular lactate concentration in HTB63 cells following 72h of transfection with siRNAs as described for B. N = 6. (E) ECAR was measured in A2058 cells using an XF24 bioanalyser following 12h of rWNT5A treatment. ΔECAR was calculated following a change to high glucose added after 40min of low glucose treatment. N = 5. (F) Glucose consumption in A2058 cells following rWNT5A or carrier treatment, as for A. N = 10. *P < 0.05; **P < 0.01.